Salama AK and Moschos SJ: Next steps in immuno-oncology: Enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies. Ann Oncol. 28:57–74. 2017.PubMed/NCBI View Article : Google Scholar

Sharon E: Can an immune checkpoint inhibitor (Sometimes) make things worse? Clin Cancer Res. 23:1879–1881. 2017.PubMed/NCBI View Article : Google Scholar

Hwang I, Park I, Yoon SK and Lee JL: Hyperprogressive disease in patients with urothelial carcinoma or renal cell carcinoma treated with PD-1/PD-L1 inhibitors. Clin Genitourin Cancer. 18:e122–e133. 2020.PubMed/NCBI View Article : Google Scholar

Kim CG, Kim KH, Pyo KH, Xin CF, Hong MH, Ahn BC, Kim Y, Choi SJ, Yoon HI, Lee JG, et al: Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer. Ann Oncol. 30:1104–1113. 2019.PubMed/NCBI View Article : Google Scholar

Petrioli R, Mazzei MA, Giorgi S, Cesqui E, Gentili F, Francini G, Volterrani L and Francini E: Hyperprogressive disease in advanced cancer patients treated with nivolumab: A case series study. Anticancer Drugs. 31:190–195. 2020.PubMed/NCBI View Article : Google Scholar

Chubachi S, Yasuda H, Irie H, Fukunaga K, Naoki K, Soejima K and Betsuyaku T: A case of non-small cell lung cancer with possible ‘disease flare’ on nivolumab treatment. Case Rep Oncol Med. 2016(1075641)2016.PubMed/NCBI View Article : Google Scholar

Lahmar J, Mezquita L, Koscielny S, Facchinetti F, Bluthgen MV, Adam J, Gazzah A, Remon J, Planchard D, Soria JC, et al: Immune checkpoint inhibitors (ICI) induce paradoxical progression in a subset of non-small cell lung cancer (NSCLC). Ann Oncol. 27 (Suppl 6)(VI423)2016.

Champiat S, Dercle L, Ammari S, Massard C, Hollebecque A, Postel-Vinay S, Chaput N, Eggermont A, Marabelle A, Soria JC and Ferté C: Hyperprogressive disease is a new pattern of progression in cancer patients treated by Anti-PD-1/PD-L1. Clin Cancer Res. 23:1920–1928. 2017.PubMed/NCBI View Article : Google Scholar

Kato S, Goodman A, Walavalkar V, Barkauskas DA, Sharabi A and Kurzrock R: Hyperprogressors after immunotherapy: Analysis of genomic alterations associated with accelerated growth rate. Clin Cancer Res. 23:4242–4250. 2017.PubMed/NCBI View Article : Google Scholar

Park HJ, Kim KW, Won SE, Yoon S, Chae YK, Tirumani SH and Ramaiya NH: Definition, incidence, and challenges for assessment of hyperprogressive disease during cancer treatment with immune checkpoint inhibitors: A systematic review and meta-analysis. JAMA Netw Open. 4(e211136)2021.PubMed/NCBI View Article : Google Scholar

Ferrara R, Mezquita L, Texier M, Lahmar J, Audigier-Valette C, Tessonnier L, Mazieres J, Zalcman G, Brosseau S, Le Moulec S, et al: Hyperprogressive disease in patients with advanced non-small cell lung cancer treated With PD-1/PD-L1 inhibitors or with single-agent chemotherapy. JAMA Oncol. 4:1543–1552. 2018.PubMed/NCBI View Article : Google Scholar

Di Giacomo AM, Danielli R, Guidoboni M, Calabrò L, Carlucci D, Miracco C, Volterrani L, Mazzei MA, Biagioli M, Altomonte M and Maio M: Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: Clinical and immunological evidence from three patient cases. Cancer Immunol Immunother. 58:1297–1306. 2009.PubMed/NCBI View Article : Google Scholar

Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G, et al: Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clin Cancer Res. 15:7412–7420. 2009.PubMed/NCBI View Article : Google Scholar

Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH Jr, Lao CD, et al: Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 16:375–384. 2015.PubMed/NCBI View Article : Google Scholar

Long GV, Weber JS, Larkin J, Atkinson V, Grob JJ, Schadendorf D, Dummer R, Robert C, Márquez-Rodas I, McNeil C, et al: Nivolumab for patients with advanced melanoma treated beyond progression: Analysis of 2 phase 3 clinical trials. JAMA Oncol. 3:1511–1519. 2017.PubMed/NCBI View Article : Google Scholar

Nishino M, Giobbie-Hurder A, Manos MP, Bailey N, Buchbinder EI, Ott PA, Ramaiya NH and Hodi FS: Immune-Related tumor response dynamics in melanoma patients treated with pembrolizumab: Identifying markers for clinical outcome and treatment decisions. Clin Cancer Res. 23:4671–4679. 2017.PubMed/NCBI View Article : Google Scholar

Motzer RJ, Rini BI, McDermott DF, Redman BG, Kuzel TM, Harrison MR, Vaishampayan UN, Drabkin HA, George S, Logan TF, et al: Nivolumab for metastatic renal cell carcinoma: Results of a randomized phase II trial. J Clin Oncol. 33:1430–1437. 2015.PubMed/NCBI View Article : Google Scholar

Nishino M, Ramaiya NH, Chambers ES, Adeni AE, Hatabu H, Jänne PA, Hodi FS and Awad MM: Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients. J Immunother Cancer. 4(84)2016.PubMed/NCBI View Article : Google Scholar

Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, et al: Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 373:123–135. 2015.PubMed/NCBI View Article : Google Scholar

Haddad R, Concha-Benavente F, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Kasper S, Vokes EE, Worden F, et al: Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial. Cancer. 125:3208–3218. 2019.PubMed/NCBI View Article : Google Scholar

Aquino D, Gioppo A, Finocchiaro G, Bruzzone MG and Cuccarini V: MRI in glioma immunotherapy: Evidence, pitfalls, and perspectives. J Immunol Res. 2017(5813951)2017.PubMed/NCBI View Article : Google Scholar

Elias R, Kapur P, Pedrosa I and Brugarolas J: Renal cell carcinoma pseudoprogression with clinical deterioration: To hospice and back. Clin Genitourin Cancer. 16:485–488. 2018.PubMed/NCBI View Article : Google Scholar

Wagner MJ, Ricciotti RW, Mantilla J, Loggers ET, Pollack SM and Cranmer LD: Response to PD1 inhibition in conventional chondrosarcoma. J Immunother Cancer. 6(94)2018.PubMed/NCBI View Article : Google Scholar

Michalarea V, Fontana E, Garces AI, Williams A, Smyth EC, Picchia S, Rao S, Chau I, Cunningham D and Bali MA: Pseudoprogression on treatment with immune-checkpoint inhibitors in patients with gastrointestinal malignancies: Case series and short literature review. Curr Probl Cancer. 43:487–494. 2019.PubMed/NCBI View Article : Google Scholar

Mamdani H, Wu H, O'Neil BH and Sehdev A: Excellent response to Anti-PD-1 therapy in a patient with hepatocellular carcinoma: Case report and review of literature. Discov Med. 23:331–336. 2017.PubMed/NCBI

Basler L, Gabryś HS, Hogan SA, Pavic M, Bogowicz M, Vuong D, Tanadini-Lang S, Förster R, Kudura K, Huellner MW, et al: Radiomics, tumor volume, and blood biomarkers for early prediction of pseudoprogression in patients with metastatic melanoma treated with immune checkpoint inhibition. Clin Cancer Res. 26:4414–4425. 2020.PubMed/NCBI View Article : Google Scholar

Solana R, Tarazona R, Gayoso I, Lesur O, Dupuis G and Fulop T: Innate immunosenescence: Effect of aging on cells and receptors of the innate immune system in humans. Semin Immunol. 24:331–341. 2012.PubMed/NCBI View Article : Google Scholar

Goronzy JJ and Weyand CM: Understanding immunosenescence to improve responses to vaccines. Nat Immunol. 14:428–436. 2013.PubMed/NCBI View Article : Google Scholar

Kanjanapan Y, Day D, Wang L, Al-Sawaihey H, Abbas E, Namini A, Siu LL, Hansen A, Razak AA, Spreafico A, et al: Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities. Cancer. 125:1341–1349. 2019.PubMed/NCBI View Article : Google Scholar

Conforti F, Pala L, Bagnardi V, De Pas T, Martinetti M, Viale G, Gelber RD and Goldhirsch A: Cancer immunotherapy efficacy and patients' sex: A systematic review and meta-analysis. Lancet Oncol. 19:737–746. 2018.PubMed/NCBI View Article : Google Scholar

Conforti F, Pala L and Goldhirsch A: Different effectiveness of anticancer immunotherapy in men and women relies on sex-dimorphism of the immune system. Oncotarget. 9:31167–31168. 2018.PubMed/NCBI View Article : Google Scholar

Polanczyk MJ, Hopke C, Vandenbark AA and Offner H: Treg suppressive activity involves estrogen-dependent expression of programmed death-1 (PD-1). Int Immunol. 19:337–343. 2007.PubMed/NCBI View Article : Google Scholar

Saâda-Bouzid E, Defaucheux C, Karabajakian A, Coloma VP, Servois V, Paoletti X, Even C, Fayette J, Guigay J, Loirat D, et al: Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol. 28:1605–1611. 2017.PubMed/NCBI View Article : Google Scholar

Yoshida T, Furuta H and Hida T: Risk of tumor flare after nivolumab treatment in patients with irradiated field recurrence. Med Oncol. 34(34)2017.PubMed/NCBI View Article : Google Scholar

Ogata T, Satake H, Ogata M, Hatachi Y and Yasui H: Hyperprogressive Disease in the irradiation field after a single dose of nivolumab for gastric cancer: A case report. Case Rep Oncol. 11:143–150. 2018.PubMed/NCBI View Article : Google Scholar

Sasaki A, Nakamura Y, Mishima S, Kawazoe A, Kuboki Y, Bando H, Kojima T, Doi T, Ohtsu A, Yoshino T, et al: Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer. Gastric Cancer. 22:793–802. 2019.PubMed/NCBI View Article : Google Scholar

Wang S, Zhao Y, Aguilar A, Bernard D and Yang CY: Targeting the MDM2-p53 protein-protein interaction for new cancer therapy: Progress and challenges. Cold Spring Harb Perspect Med. 7(a026245)2017.PubMed/NCBI View Article : Google Scholar

Peng W, Liu C, Xu C, Lou Y, Chen J, Yang Y, Yagita H, Overwijk WW, Lizée G, Radvanyi L and Hwu P: PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines. Cancer Res. 72:5209–5218. 2012.PubMed/NCBI View Article : Google Scholar

Sakai S, Kauffman KD, Sallin MA, Sharpe AH, Young HA, Ganusov VV and Barber DL: CD4 T Cell-Derived IFN-γ plays a minimal role in control of pulmonary mycobacterium tuberculosis infection and must be actively repressed by PD-1 to prevent lethal disease. PLoS Pathog. 12(e1005667)2016.PubMed/NCBI View Article : Google Scholar

Singavi AK, Menon S, Kilari D, Alqwasmi A, Ritch PS, Thomas JP, Martin AL, Oxencis C, Ali SM and George B: 1140PDPredictive biomarkers for hyper-progression (HP) in response to immune checkpoint inhibitors (ICI)-analysis of somatic alterations (SAs). Ann Oncol. 28 (Suppl 5):2017.

Giusti R, Mazzotta M, Filetti M, Marinelli D, Di Napoli A, Scarpino S, Scafetta G, Mei M, Vecchione A, Ruco L and Marchetti P: CDKN2A/B gene loss and MDM2 alteration as a potential molecular signature for hyperprogressive disease in advanced NSCLC: A next-generation-sequencing approach. J Clin Oncol. 37(e20628)2019.

Kamada T, Togashi Y, Tay C, Ha D, Sasaki A, Nakamura Y, Sato E, Fukuoka S, Tada Y, Tanaka A, et al: PD-1(+) regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer. Proc Natl Acad Sci USA. 116:9999–10008. 2019.PubMed/NCBI View Article : Google Scholar

Li L, Zhang J, Jiang X and Li Q: Promising clinical application of ctDNA in evaluating immunotherapy efficacy. Am J Cancer Res. 8:1947–1956. 2018.PubMed/NCBI

McClelland SE: Role of chromosomal instability in cancer progression. Endocr Relat Cancer. 24:T23–T31. 2017.PubMed/NCBI View Article : Google Scholar

Han XJ, Alu A, Xiao YN, Wei YQ and Wei XW: Hyperprogression: A novel response pattern under immunotherapy. Clin Transl Med. 10(e167)2020.PubMed/NCBI View Article : Google Scholar

Boussiotis VA: Molecular and biochemical aspects of the PD-1 checkpoint pathway. N Engl J Med. 375:1767–1778. 2016.PubMed/NCBI View Article : Google Scholar

Rosenberg SA, Spiess P and Lafreniere R: A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science. 233:1318–1321. 1986.PubMed/NCBI View Article : Google Scholar

Adeegbe DO and Nishikawa H: Natural and induced T regulatory cells in cancer. Front Immunol. 4(190)2013.PubMed/NCBI View Article : Google Scholar

Wen L, Lu H, Li Q, Wen S, Wang D, Wang X, Fang J, Cui J, Cheng B and Wang Z: Contributions of T cell dysfunction to the resistance against anti-PD-1 therapy in oral carcinogenesis. J Exp Clin Cancer Res. 38(299)2019.PubMed/NCBI View Article : Google Scholar

Oweida A, Hararah MK, Phan A, Binder D, Bhatia S, Lennon S, Bukkapatnam S, Van Court B, Uyanga N, Darragh L, et al: Resistance to Radiotherapy and PD-L1 Blockade Is Mediated by TIM-3 Upregulation and Regulatory T-Cell Infiltration. Clin Cancer Res. 24:5368–5380. 2018.PubMed/NCBI View Article : Google Scholar

Di Pilato M, Kim EY, Cadilha BL, Prüßmann JN, Nasrallah MN, Seruggia D, Usmani SM, Misale S, Zappulli V, Carrizosa E, et al: Targeting the CBM complex causes T(reg) cells to prime tumours for immune checkpoint therapy. Nature. 570:112–116. 2019.PubMed/NCBI View Article : Google Scholar

Jacquelot N, Yamazaki T, Roberti MP, Duong CPM, Andrews MC, Verlingue L, Ferrere G, Becharef S, Vétizou M, Daillère R, et al: Sustained type I interferon signaling as a mechanism of resistance to PD-1 blockade. Cell Res. 29:846–861. 2019.PubMed/NCBI View Article : Google Scholar

Kumagai S, Togashi Y, Kamada T, Sugiyama E, Nishinakamura H, Takeuchi Y, Vitaly K, Itahashi K, Maeda Y, Matsui S, et al: The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies. Nat Immunol. 21:1346–1358. 2020.PubMed/NCBI View Article : Google Scholar

Lo Russo G, Moro M, Sommariva M, Cancila V, Boeri M, Centonze G, Ferro S, Ganzinelli M, Gasparini P, Huber V, et al: Antibody-Fc/FcR interaction on macrophages as a mechanism for hyperprogressive disease in non-small cell lung cancer subsequent to PD-1/PD-L1 blockade. Clin Cancer Res. 25:989–999. 2019.PubMed/NCBI View Article : Google Scholar

Movahedi K, Laoui D, Gysemans C, Baeten M, Stangé G, Van den Bossche J, Mack M, Pipeleers D, In't Veld P, De Baetselier P and Van Ginderachter JA: Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res. 70:5728–5739. 2010.PubMed/NCBI View Article : Google Scholar

Henze AT and Mazzone M: The impact of hypoxia on tumor-associated macrophages. J Clin Invest. 126:3672–3679. 2016.PubMed/NCBI View Article : Google Scholar

Wang C, Yu Q, Song T, Wang Z, Song L, Yang Y, Shao J, Li J, Ni Y, Chao N, et al: The heterogeneous immune landscape between lung adenocarcinoma and squamous carcinoma revealed by single-cell RNA sequencing. Signal Transduct Target Ther. 7(289)2022.PubMed/NCBI View Article : Google Scholar

Patten DA and Shetty S: The role of stabilin-1 in lymphocyte trafficking and macrophage scavenging in the liver microenvironment. Biomolecules. 9(283)2019.PubMed/NCBI View Article : Google Scholar

Liu Y, Zhang L, Ju X, Wang S and Qie J: Single-Cell transcriptomic analysis reveals macrophage-tumor crosstalk in hepatocellular carcinoma. Front Immunol. 13(955390)2022.PubMed/NCBI View Article : Google Scholar

Xu Z, Chang CC, Li M, Zhang QY, Vasilescu EM, D'Agati V, Floratos A, Vlad G and Suciu-Foca N: ILT3.Fc-CD166 interaction induces inactivation of p70 S6 kinase and inhibits tumor cell growth. J Immunol. 200:1207–1219. 2018.PubMed/NCBI View Article : Google Scholar

Willoughby JE, Kerr JP, Rogel A, Taraban VY, Buchan SL, Johnson PW and Al-Shamkhani A: Differential impact of CD27 and 4-1BB costimulation on effector and memory CD8 T cell generation following peptide immunization. J Immunol. 193:244–251. 2014.PubMed/NCBI View Article : Google Scholar

Chen L, Xu Z, Chang C, Ho S, Liu Z, Vlad G, Cortesini R, Clynes RA, Luo Y and Suciu-Foca N: Allospecific CD8 T suppressor cells induced by multiple MLC stimulation or priming in the presence of ILT3.Fc have similar gene expression profiles. Hum Immunol. 75:190–196. 2014.PubMed/NCBI View Article : Google Scholar

Vlad G and Suciu-Foca N: Induction of antigen-specific human T suppressor cells by membrane and soluble ILT3. Exp Mol Pathol. 93:294–301. 2012.PubMed/NCBI View Article : Google Scholar

Braza MKE, Gazmen JDN, Yu ET and Nellas RB: Ligand-Induced conformational dynamics of a tyramine receptor from sitophilus oryzae. Sci Rep. 9(16275)2019.PubMed/NCBI View Article : Google Scholar

Mukherjee A, Acharya S, Purkait K, Chakraborty K, Bhattacharjee A and Mukherjee A: Effect of N,N Coordination and Ru(II) Halide Bond in Enhancing Selective Toxicity of a Tyramine-Based Ru(II) (p-Cymene) Complex. Inorg Chem. 59:6581–6594. 2020.PubMed/NCBI View Article : Google Scholar

Chen HM, van der Touw W, Wang YS, Kang K, Mai S, Zhang J, Alsina-Beauchamp D, Duty JA, Mungamuri SK, Zhang B, et al: Blocking immunoinhibitory receptor LILRB2 reprograms tumor-associated myeloid cells and promotes antitumor immunity. J Clin Invest. 128:5647–5662. 2018.PubMed/NCBI View Article : Google Scholar

Li G, Choi JE, Kryczek I, Sun Y, Liao P, Li S, Wei S, Grove S, Vatan L, Nelson R, et al: Intersection of immune and oncometabolic pathways drives cancer hyperprogression during immunotherapy. Cancer Cell. 41:304–322.e7. 2023.PubMed/NCBI View Article : Google Scholar